,4 Using an existing real-world data set of patients diagnosed with NSCLC in 2019 in the Netherlands,5 we examined whether differences in survival pattern on the basis of KRAS/TP53 mutational status could be observed in the entire population of patients with metastatic NSCLC who were treated with first-line immunotherapy, either as monotherapy or in combination with chemotherapy. This evidence concerns the gene TP53 and non-small cell lung carcinoma.